Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance.
Giuffrida G, Markovic U, Condorelli A, Duminuco A, Calafiore V, Conticello C, Romano A, Grasso S, Riccobene C, Ragusa MTV, Esposito B, Nicolosi D, Calagna M, Nardo A, Consoli U, Uccello G, Di Giacomo V, Neri S, Cingari MR, Rodà F, Innao V, Fiumara A, Duro G, Zizzo C, Di Raimondo F. Giuffrida G, et al. Among authors: uccello g. Eur J Haematol. 2023 Dec;111(6):922-929. doi: 10.1111/ejh.14105. Epub 2023 Sep 25. Eur J Haematol. 2023. PMID: 37747757
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey.
Markovic U, Romano A, Del Fabro V, Bellofiore C, Bulla A, Parisi MS, Leotta S, Gentile M, Cangialosi C, Vincelli I, Mineo G, Rossi M, Poidomani M, Uccello G, Maugeri C, Mannina D, Innao V, Di Raimondo F, Conticello C. Markovic U, et al. Among authors: uccello g. Front Oncol. 2021 Mar 5;11:624405. doi: 10.3389/fonc.2021.624405. eCollection 2021. Front Oncol. 2021. PMID: 33763359 Free PMC article.
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network.
Conticello C, Romano A, Del Fabro V, Martino EA, Calafiore V, Sapienza G, Leotta V, Parisi MS, Markovic U, Garibaldi B, Leotta S, Cotzia E, Innao V, Mannina D, Neri S, Musso M, Scalone R, Cangialosi C, Acquaviva F, Cardinale G, Merenda A, Maugeri C, Uccello G, Poidomani M, Longo G, Carlisi M, Tibullo D, Di Raimondo F. Conticello C, et al. Among authors: uccello g. J Clin Med. 2019 Jun 19;8(6):877. doi: 10.3390/jcm8060877. J Clin Med. 2019. PMID: 31248142 Free PMC article.
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.
Gentile M, Specchia G, Derudas D, Galli M, Botta C, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Attingenti E, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Musto P, Capalbo S, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Fraticelli V, Vincelli D, Bonalumi A, Siniscalchi A, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Recchia AG, Tripepi G, Pitino A, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Boccadoro M, Cavo M, Morabito F. Gentile M, et al. Among authors: uccello g. Haematologica. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513. Haematologica. 2021. PMID: 32107338 Free PMC article. No abstract available.
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Bruzzese A, Derudas D, Galli M, Martino EA, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Farina G, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Pietrantuono G, Palumbo G, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Mendicino F, Iaccino E, Mimmi S, Botta C, Vincelli D, Sgherza N, Bonalumi A, Cupelli L, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Tripepi G, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Musto P, Boccadoro M, Cavo M, Neri A, Morabito F, Gentile M. Bruzzese A, et al. Among authors: uccello g. Hematol Oncol. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1. Hematol Oncol. 2022. PMID: 35608183 Free article.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Gentile M, Vigna E, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Martino EA, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pompa A, Vincelli D, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Ferretti E, Bertuglia G, Nappi D, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P. Gentile M, et al. Among authors: uccello g. Haematologica. 2024 Jan 1;109(1):245-255. doi: 10.3324/haematol.2023.283251. Haematologica. 2024. PMID: 37439329 Free PMC article.
Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Gentile M, Magarotto V, Offidani M, Musto P, Bringhen S, Teresa Petrucci M, Gay F, Larocca A, Uccello G, Petrungaro A, Vigna E, Greco R, Grazia Recchia A, Tripepi G, Ria R, Di Raimondo F, Palumbo A, Morabito F. Gentile M, et al. Among authors: uccello g. Am J Hematol. 2017 Mar;92(3):244-250. doi: 10.1002/ajh.24621. Epub 2017 Jan 23. Am J Hematol. 2017. PMID: 28006855 Free article. Clinical Trial.
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F. Gentile M, et al. Among authors: uccello g. Leukemia. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6. Epub 2018 Mar 20. Leukemia. 2018. PMID: 29588545 No abstract available.
Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia.
Mauro FR, Morabito F, Vincelli ID, Petrucci L, Campanelli M, Salaroli A, Uccello G, Petrungaro A, Ronco F, Raponi S, Nanni M, Neri A, Ferrarini M, Guarini AR, Foà R, Gentile M. Mauro FR, et al. Among authors: uccello g. Leuk Res. 2017 Jun;57:65-71. doi: 10.1016/j.leukres.2017.02.011. Epub 2017 Feb 27. Leuk Res. 2017. PMID: 28292720
42 results